Daniel A. Weiser

962 total citations
35 papers, 529 citations indexed

About

Daniel A. Weiser is a scholar working on Neurology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Daniel A. Weiser has authored 35 papers receiving a total of 529 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Neurology, 11 papers in Molecular Biology and 10 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Daniel A. Weiser's work include Neuroblastoma Research and Treatments (12 papers), Sarcoma Diagnosis and Treatment (8 papers) and Cancer Genomics and Diagnostics (6 papers). Daniel A. Weiser is often cited by papers focused on Neuroblastoma Research and Treatments (12 papers), Sarcoma Diagnosis and Treatment (8 papers) and Cancer Genomics and Diagnostics (6 papers). Daniel A. Weiser collaborates with scholars based in United States, China and Australia. Daniel A. Weiser's co-authors include Yaël P. Mossé, Kateryna Krytska, Eric Rappaport, Wendy B. London, Jin H. Park, Andrew Wood, Ravi Radhakrishnan, Peter J. Huwe, Mark A. Lemmon and Michael D. Hogarty and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Cell.

In The Last Decade

Daniel A. Weiser

33 papers receiving 524 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Daniel A. Weiser United States 11 259 250 185 161 144 35 529
Pablo Berlanga France 12 186 0.7× 140 0.6× 97 0.5× 181 1.1× 167 1.2× 54 492
Vinay M. Daryani United States 14 183 0.7× 75 0.3× 60 0.3× 126 0.8× 128 0.9× 16 462
A. D. J. Pearson United Kingdom 11 220 0.8× 273 1.1× 104 0.6× 114 0.7× 66 0.5× 17 506
Christopher Lawlor United States 4 332 1.3× 53 0.2× 107 0.6× 110 0.7× 54 0.4× 7 548
M Buclon France 11 258 1.0× 97 0.4× 147 0.8× 183 1.1× 284 2.0× 17 553
Bartłomiej Tomasik Poland 14 247 1.0× 48 0.2× 189 1.0× 145 0.9× 167 1.2× 74 619
Margaret Ottaviano Italy 11 153 0.6× 98 0.4× 43 0.2× 193 1.2× 71 0.5× 62 450
E. Stanton Adkins United States 8 455 1.8× 687 2.7× 242 1.3× 134 0.8× 64 0.4× 13 895
Timothy D. Byrne United States 7 141 0.5× 265 1.1× 89 0.5× 54 0.3× 50 0.3× 10 382
Yi Que China 14 193 0.7× 39 0.2× 84 0.5× 347 2.2× 208 1.4× 51 595

Countries citing papers authored by Daniel A. Weiser

Since Specialization
Citations

This map shows the geographic impact of Daniel A. Weiser's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel A. Weiser with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel A. Weiser more than expected).

Fields of papers citing papers by Daniel A. Weiser

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel A. Weiser. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel A. Weiser. The network helps show where Daniel A. Weiser may publish in the future.

Co-authorship network of co-authors of Daniel A. Weiser

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel A. Weiser. A scholar is included among the top collaborators of Daniel A. Weiser based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel A. Weiser. Daniel A. Weiser is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Geohagen, Brian C., Kimberly Reidy, Tao Wang, et al.. (2022). Acetophenone protection against cisplatin-induced end-organ damage. Translational Oncology. 27. 101595–101595. 2 indexed citations
3.
4.
Landesman, Yosef, Bruce Pawel, Stephen R. Master, et al.. (2021). XPO1 inhibition with selinexor synergizes with proteasome inhibition in neuroblastoma by targeting nuclear export of IkB. Translational Oncology. 14(8). 101114–101114. 20 indexed citations
5.
Church, Alanna J., Laura Corson, Pei‐Chi Kao, et al.. (2021). Clinical impact of molecular tumor profiling in pediatric, adolescent, and young adult patients with extra-cranial solid malignancies: An interim report from the GAIN/iCat2 study.. Journal of Clinical Oncology. 39(15_suppl). 10005–10005. 2 indexed citations
6.
Yan, Jingqi, Hiyaa S. Ghosh, Karina Alviña, et al.. (2021). Donor-derived vasculature is required to support neocortical cell grafts after stroke. Stem Cell Research. 59. 102642–102642. 5 indexed citations
7.
Wang, Jichuan, Kenji Satô, Amit Singla, et al.. (2020). Skp2 depletion reduces tumor-initiating properties and promotes apoptosis in synovial sarcoma. Translational Oncology. 13(10). 100809–100809. 17 indexed citations
8.
Rybinski, Brad, et al.. (2020). Preclinical Metrics Correlate With Drug Activity in Phase II Trials of Targeted Therapies for Non-Small Cell Lung Cancer. Frontiers in Oncology. 10. 587377–587377. 1 indexed citations
9.
Geohagen, Brian C., et al.. (2020). Enolate-forming compounds provide protection from platinum neurotoxicity. Chemico-Biological Interactions. 317. 108961–108961. 2 indexed citations
10.
Weiser, Daniel A., et al.. (2019). Otolaryngologist and pediatric oncologist perspectives on the role of fine needle aspiration in diagnosing pediatric head and neck masses. International Journal of Pediatric Otorhinolaryngology. 121. 34–40.
11.
Weiser, Daniel A., et al.. (2019). Progress toward liquid biopsies in pediatric solid tumors. Cancer and Metastasis Reviews. 38(4). 553–571. 42 indexed citations
12.
Bailey, Kayleen, Michael Roth, Daniel A. Weiser, & Jonathan Gill. (2018). High-Dose Chemotherapy with Stem Cell Rescue in Desmoplastic Small Round Cell Tumor: A Single-Institution Experience and Review of the Literature. Sarcoma. 2018. 1–10. 5 indexed citations
13.
Quispe‐Tintaya, Wilber, Moonsook Lee, Xiao Dong, et al.. (2018). Bleomycin-induced genome structural variations in normal, non-tumor cells. Scientific Reports. 8(1). 16523–16523. 13 indexed citations
14.
Rybinski, Brad, et al.. (2018). Systemic manifestations of extraskeletal myxoid chondrosarcoma associated with a novel t(2;22)(q34;q12) EWS translocation in a child and a review of the literature. Pediatric Hematology and Oncology. 35(7-8). 434–441. 1 indexed citations
15.
Dubin, Robert, Michael A. Fremed, Xusheng Zhang, et al.. (2018). Detection of circulating tumor DNA in patients with osteosarcoma. Oncotarget. 9(16). 12695–12704. 37 indexed citations
16.
Castellanos, Raquel, et al.. (2016). Abstract 2481A: A novel chemically-modified curcumin (CMC 2.24) promotes chemosensitivity in neuroblastoma. Cancer Research. 76(14_Supplement). 2481A–2481A. 1 indexed citations
17.
Fremed, Michael A., Terry L. Levin, Katherine Sun, & Daniel A. Weiser. (2015). Ovary preservation in the treatment of childhood Meigs syndrome. Pediatric Blood & Cancer. 62(11). 2011–2014. 6 indexed citations
18.
Niazi, Muhammad Khalid Khan, Daniel A. Weiser, Bruce Pawel, & Metin N. Gürcan. (2015). Characterizing primary refractory neuroblastoma: prediction of outcome by microscopic image analysis. Proceedings of SPIE, the International Society for Optical Engineering/Proceedings of SPIE. 9420. 942008–942008. 1 indexed citations
19.
Bresler, Scott C., Daniel A. Weiser, Peter J. Huwe, et al.. (2014). ALK Mutations Confer Differential Oncogenic Activation and Sensitivity to ALK Inhibition Therapy in Neuroblastoma. Cancer Cell. 26(5). 682–694. 252 indexed citations
20.
Weiser, Daniel A., Sue C. Kaste, Marilyn J. Siegel, & Peter C. Adamson. (2013). Imaging in childhood cancer: A society for pediatric radiology and children's oncology group joint task force report. Pediatric Blood & Cancer. 60(8). 1253–1260. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Pablo Berlanga Breakdown of academic impact, for papers by Vinay M. Daryani Breakdown of academic impact, for papers by A. D. J. Pearson Breakdown of academic impact, for papers by Christopher Lawlor Breakdown of academic impact, for papers by M Buclon Breakdown of academic impact, for papers by Bartłomiej Tomasik Breakdown of academic impact, for papers by Margaret Ottaviano Breakdown of academic impact, for papers by E. Stanton Adkins Breakdown of academic impact, for papers by Timothy D. Byrne Breakdown of academic impact, for papers by Yi Que
Rankless by CCL
2026